Children with antineutrophil cytoplasmic antibody–associated vasculitis had similar remissions rates with rituximab and ...

A preliminary study showed that four weekly doses of intravenous rituximab, an anti-B-cell antibody, reduced proteinuria in patients with idiopathic membranous nephropathy, but individual ...

Understanding RILD's clinical characteristics is essential for effective management in patients undergoing immunochemotherapy ...

To stabilize this condition we started rituximab therapy immediately after the third cycle of immunoadsorption, with 375 mg/m 2 rituximab being administered intravenously once weekly for 4 weeks.

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...

APG-2575（Lisaftoclax）是亚盛医药自主研发的、具全球best-in-class潜力的新型口服Bcl-2选择性抑制剂，在多种血液肿瘤和实体瘤治疗领域具备广阔的治疗潜力。亚盛医药将在此次ASH年会上，口头报告该品种治疗复发/难治（R/R）多发性骨髓瘤 ...

Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands. Its biosimilar of Roche’s ...

In an exclusive interview with Moneycontrol, Dr Reddy's CFO, M.V. Narasimham highlighted the company's plans on moving up the ...

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases.

Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in ...

Tacrolimus, cyclosporin, mycophenolate mofetil, and levamisole may reduce the risk of relapse in children with frequently relapsing nephrotic syndrome. Cyclophosphamide and chlorambucil compared with ...

Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes #469 oral presentation Session: 626.